Spliceosomes are large molecular machines inside your cells that edit genetic messages before they can be used to build proteins. When a gene is first copied from DNA into a preliminary RNA transcript, that transcript contains both useful segments (exons) and non-coding segments (introns) that need to be cut out. The spliceosome does this cutting and stitching, joining the exons together into a finished message the cell can read. The average human gene contains 8 to 9 introns, so nearly every protein your body makes depends on this editing process.
What Spliceosomes Are Made Of
A spliceosome is not a single molecule. It is a massive complex built from five smaller units called small nuclear ribonucleoproteins (snRNPs, pronounced “snurps”) and well over a hundred additional proteins. The five snRNPs are named U1, U2, U4, U5, and U6. Each one contains a short strand of RNA plus its own set of proteins, and they come together in a specific order around the RNA transcript that needs editing.
Proteomic studies of human spliceosomes show that over 170 different proteins associate with the complex at various points during splicing, though any single snapshot of the machine in action catches around 110 proteins at a time. This makes the spliceosome one of the largest and most dynamic molecular structures in the cell, comparable in complexity to the ribosome (the machine that builds proteins).
How Spliceosomes Assemble Step by Step
Spliceosomes don’t sit around pre-built, waiting for work. They assemble fresh on each RNA transcript, snapping together in a carefully ordered sequence. This assembly happens in stages, each named after the complex it produces.
In the first stage, the U1 snRNP latches onto the beginning of an intron (the 5′ splice site) while helper proteins recognize the end of the intron and a critical landmark within it called the branch point. This loose early arrangement is called Complex E, and it forms without the cell spending any energy. It is stabilized by additional protein factors that help confirm the splice sites are in the right places.
Next, the U2 snRNP locks onto the branch point sequence in an energy-requiring step, forming Complex A. At this stage, a short stretch of U2’s RNA pairs with the RNA transcript in a way that forces a specific adenosine nucleotide to bulge outward, positioning it to act as the chemical trigger for the first cut. The interactions between U1 and U2 also pull the two ends of the intron close together.
Then, the remaining three snRNPs arrive as a pre-assembled trio (U4/U6 joined with U5), creating Complex B. This triggers a dramatic reshuffling: U1 and U4 are released from the complex, new RNA-RNA pairings form between U2 and U6, and the spliceosome becomes catalytically active. This activated form, sometimes called Complex B*, is now ready to perform the actual chemistry of splicing.
The Two-Cut Chemistry
Splicing involves two precise chemical reactions, both of the same type: transesterification, which is essentially a swap of chemical bonds. In the first reaction, the bulging adenosine at the branch point attacks the beginning of the intron, cutting the RNA at that spot and forming an unusual loop structure called a lariat. The intron is now attached to itself in a lasso shape while the first exon hangs free.
In the second reaction, the free end of the first exon attacks the junction at the end of the intron, simultaneously joining the two exons together and releasing the lariat intron. The finished, spliced RNA message is then exported from the nucleus, and the lariat is broken down and recycled. The snRNPs disassemble and are free to participate in splicing another transcript.
Alternative Splicing and Protein Diversity
If spliceosomes simply removed every intron the same way every time, each gene would produce exactly one protein. But that is not what happens. Through a process called alternative splicing, the spliceosome can join exons from the same gene in different combinations, producing related but distinct RNA messages from a single gene. A gene with seven exons can, in principle, generate hundreds of different protein variants depending on which exons are included or excluded.
This is one of the reasons the human body can be so complex despite having a relatively modest number of genes (around 20,000). Alternative splicing vastly expands the protein toolkit available for everything from structural support to immune defense. The immune system, in particular, relies on alternative splicing to rapidly generate proteins tailored to fight specific viruses and bacteria.
The Minor Spliceosome
The spliceosome described above handles the vast majority of introns in human genes, but a small subset of introns (called U12-type introns) are processed by a separate, parallel machine known as the minor spliceosome. It uses its own set of snRNPs: U11 and U12 replace U1 and U2, while U4atac and U6atac replace U4 and U6. U5 is shared between both systems.
One key difference is that the minor spliceosome recognizes more tightly conserved splice site sequences, which means it has less flexibility in how it joins exons. The major spliceosome, by contrast, works with loosely conserved splice sites, giving it the wiggle room that fuels most alternative splicing. Both systems are essential, and disruption of either one causes disease.
What Happens When Splicing Goes Wrong
Because nearly every human gene requires splicing, defects in the spliceosome can have serious consequences. Mutations in core spliceosomal proteins are linked to several inherited diseases.
- Retinitis pigmentosa (RP) is one of the most common hereditary diseases tied to spliceosome mutations. Despite the spliceosome being active in every cell, mutations in six specific proteins of the U4/U6·U5 tri-snRNP complex cause a progressive degeneration of the retina that leads to vision loss. Why these mutations selectively damage the eye while sparing other tissues remains an active question in biology.
- Spinal muscular atrophy (SMA), a degenerative disease affecting motor neurons, is linked to the SMN protein, which interacts with components of the U1 snRNP. Loss of SMN disrupts the assembly of snRNPs themselves, impairing splicing broadly but hitting motor neurons hardest.
Beyond inherited diseases, splicing errors play a significant role in cancer. Many tumors carry mutations in splicing factors, and researchers have developed compounds that target the spliceosome to exploit this vulnerability. Several drugs derived from natural products bind to a subunit of the U2 snRNP and disrupt splicing in cancer cells. One orally available inhibitor, H3B-8800, preferentially slows growth in cancer cells that already carry spliceosome mutations, and it has entered early-stage clinical trials for blood cancers including myelodysplastic syndromes and acute myeloid leukemia.
Why Spliceosomes Matter Beyond Biology Class
Spliceosomes sit at the heart of gene expression in all complex life. More than 95% of human genes with multiple exons undergo some form of alternative splicing, making the spliceosome a central player not just in routine cell maintenance but in the diversity of proteins that define tissues, organs, and immune responses. Understanding how this machine works has opened doors to diagnosing genetic diseases at the RNA level and designing therapies that correct or exploit splicing errors. For a structure most people have never heard of, the spliceosome quietly shapes almost everything your cells do.